Biodesix, Inc.
BDSX
$15.90
$0.684.47%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 96.10M | 88.50M | 80.17M | 76.56M | 74.46M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 96.10M | 88.50M | 80.17M | 76.56M | 74.46M |
| Cost of Revenue | 17.62M | 16.72M | 16.18M | 16.26M | 16.10M |
| Gross Profit | 78.48M | 71.78M | 63.99M | 60.30M | 58.36M |
| SG&A Expenses | 91.36M | 87.55M | 84.79M | 83.09M | 80.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 121.40M | 116.27M | 112.52M | 110.45M | 106.83M |
| Operating Income | -25.30M | -27.77M | -32.35M | -33.89M | -32.37M |
| Income Before Tax | -31.96M | -35.27M | -39.54M | -41.08M | -40.42M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -31.96 | -35.27 | -39.54 | -41.08 | -40.42 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -31.96M | -35.27M | -39.54M | -41.08M | -40.42M |
| EBIT | -25.30M | -27.77M | -32.35M | -33.89M | -32.37M |
| EBITDA | -19.67M | -22.10M | -26.61M | -28.08M | -26.58M |
| EPS Basic | -4.03 | -4.74 | -5.37 | -5.61 | -5.75 |
| Normalized Basic EPS | -2.54 | -2.95 | -3.34 | -3.49 | -3.55 |
| EPS Diluted | -4.03 | -4.74 | -5.37 | -5.61 | -5.75 |
| Normalized Diluted EPS | -2.54 | -2.95 | -3.34 | -3.49 | -3.55 |
| Average Basic Shares Outstanding | 32.55M | 30.20M | 29.46M | 29.28M | 28.30M |
| Average Diluted Shares Outstanding | 32.55M | 30.20M | 29.46M | 29.28M | 28.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |